Abstract
Introduction: Immune checkpoint inhibitors (ICIs) have demonstrated long survival for the treatment of advanced non-small cell lung cancer (NSCLC). However, the effect and safety of ICI rechallenge have not been fully evaluated. The aim of this study was to investigate the efficacy and safety of ICI rechallenge in NSCLC patients. Methods: We defined ‘rechallenge’ as re-administration of ICIs for patients who were previously treated with ICIs and discontinued treatment for any reason, and received subsequent chemotherapy. We retrospectively analyzed the histories of 434 patients with advanced NSCLC who received ICIs from December 2015 to December 2017 at seven centers. Results: A total of 317 patients discontinued the ICI treatment, and 14 patients (4.4%) received ICI rechallenge. All 14 patients discontinued the first ICI due to disease progression. Eight patients received the same kind of ICIs, and six patients received different ICIs. Median progression-free survival and overall survival were 1.5 months [95% confidence interval (CI): 0.8–2.6] and 6.5 months [95% CI: 1.4–19.0], respectively. The objective response rate was 7.1%, and the disease control rate was 21.4%. Two of three patients who achieved at least a stable disease, received radiotherapy between the first and second ICIs. Adverse events were not significantly different compared with the first ICIs. Conclusions: In this study, the effect of ICI rechallenge was limited. Careful consideration of the administration of ICI rechallenge is necessary. This report involved a small number of cases, so further large prospective studies are warranted to confirm the efficacy of ICI rechallenge and to investigate predictive markers to identify a patient population in which ICI rechallenge is effective.
| Original language | English |
|---|---|
| Pages (from-to) | 762-765 |
| Number of pages | 4 |
| Journal | Japanese journal of clinical oncology |
| Volume | 49 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 1 2019 |
Fingerprint
Keywords
- Immune checkpoint inhibitor
- Non-small cell lung cancer
- Rechallenge
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
- Cancer Research
Cite this
The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. / Watanabe, Hiromi; Kubo, Toshio; Ninomiya, Kiichiro; Kudo, Kenichiro; Minami, Daisuke; Murakami, Etsuko; Ochi, Nobuaki; Ninomiya, Takashi; Harada, Daijiro; Yasugi, Masayuki; Ichihara, Eiki; Ohashi, Kadoaki; Fujiwara, Keiichi; Hotta, Katsuyuki; Tabata, Masahiro; Maeda, Yoshinobu; Kiura, Katsuyuki.
In: Japanese journal of clinical oncology, Vol. 49, No. 8, 01.08.2019, p. 762-765.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer
AU - Watanabe, Hiromi
AU - Kubo, Toshio
AU - Ninomiya, Kiichiro
AU - Kudo, Kenichiro
AU - Minami, Daisuke
AU - Murakami, Etsuko
AU - Ochi, Nobuaki
AU - Ninomiya, Takashi
AU - Harada, Daijiro
AU - Yasugi, Masayuki
AU - Ichihara, Eiki
AU - Ohashi, Kadoaki
AU - Fujiwara, Keiichi
AU - Hotta, Katsuyuki
AU - Tabata, Masahiro
AU - Maeda, Yoshinobu
AU - Kiura, Katsuyuki
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Introduction: Immune checkpoint inhibitors (ICIs) have demonstrated long survival for the treatment of advanced non-small cell lung cancer (NSCLC). However, the effect and safety of ICI rechallenge have not been fully evaluated. The aim of this study was to investigate the efficacy and safety of ICI rechallenge in NSCLC patients. Methods: We defined ‘rechallenge’ as re-administration of ICIs for patients who were previously treated with ICIs and discontinued treatment for any reason, and received subsequent chemotherapy. We retrospectively analyzed the histories of 434 patients with advanced NSCLC who received ICIs from December 2015 to December 2017 at seven centers. Results: A total of 317 patients discontinued the ICI treatment, and 14 patients (4.4%) received ICI rechallenge. All 14 patients discontinued the first ICI due to disease progression. Eight patients received the same kind of ICIs, and six patients received different ICIs. Median progression-free survival and overall survival were 1.5 months [95% confidence interval (CI): 0.8–2.6] and 6.5 months [95% CI: 1.4–19.0], respectively. The objective response rate was 7.1%, and the disease control rate was 21.4%. Two of three patients who achieved at least a stable disease, received radiotherapy between the first and second ICIs. Adverse events were not significantly different compared with the first ICIs. Conclusions: In this study, the effect of ICI rechallenge was limited. Careful consideration of the administration of ICI rechallenge is necessary. This report involved a small number of cases, so further large prospective studies are warranted to confirm the efficacy of ICI rechallenge and to investigate predictive markers to identify a patient population in which ICI rechallenge is effective.
AB - Introduction: Immune checkpoint inhibitors (ICIs) have demonstrated long survival for the treatment of advanced non-small cell lung cancer (NSCLC). However, the effect and safety of ICI rechallenge have not been fully evaluated. The aim of this study was to investigate the efficacy and safety of ICI rechallenge in NSCLC patients. Methods: We defined ‘rechallenge’ as re-administration of ICIs for patients who were previously treated with ICIs and discontinued treatment for any reason, and received subsequent chemotherapy. We retrospectively analyzed the histories of 434 patients with advanced NSCLC who received ICIs from December 2015 to December 2017 at seven centers. Results: A total of 317 patients discontinued the ICI treatment, and 14 patients (4.4%) received ICI rechallenge. All 14 patients discontinued the first ICI due to disease progression. Eight patients received the same kind of ICIs, and six patients received different ICIs. Median progression-free survival and overall survival were 1.5 months [95% confidence interval (CI): 0.8–2.6] and 6.5 months [95% CI: 1.4–19.0], respectively. The objective response rate was 7.1%, and the disease control rate was 21.4%. Two of three patients who achieved at least a stable disease, received radiotherapy between the first and second ICIs. Adverse events were not significantly different compared with the first ICIs. Conclusions: In this study, the effect of ICI rechallenge was limited. Careful consideration of the administration of ICI rechallenge is necessary. This report involved a small number of cases, so further large prospective studies are warranted to confirm the efficacy of ICI rechallenge and to investigate predictive markers to identify a patient population in which ICI rechallenge is effective.
KW - Immune checkpoint inhibitor
KW - Non-small cell lung cancer
KW - Rechallenge
UR - http://www.scopus.com/inward/record.url?scp=85074377319&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074377319&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyz066
DO - 10.1093/jjco/hyz066
M3 - Article
C2 - 31090906
AN - SCOPUS:85074377319
VL - 49
SP - 762
EP - 765
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
SN - 0368-2811
IS - 8
ER -